Menu
Search
|

Menu

Close
X

Cleveland Biolabs Inc CBLI.OQ (NASDAQ Stock Exchange Capital Market)

1.69 USD
-- (--)
As of Nov 13
chart
Previous Close 1.69
Open --
Volume --
3m Avg Volume 3,097
Today’s High --
Today’s Low --
52 Week High 4.21
52 Week Low 1.56
Shares Outstanding (mil) 11.28
Market Capitalization (mil) 39.37
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
4
FY15
3
EPS (USD)
FY18
-0.184
FY17
-0.867
FY16
-0.242
FY15
-2.694
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
13.52
5.95
Price to Book (MRQ)
vs sector
8.54
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
0.00
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
-119.26
14.22
Return on Equity (TTM)
vs sector
-119.07
15.99

EXECUTIVE LEADERSHIP

Langdon Miller
President, Since 2015
Salary: $193,575.00
Bonus: --
Yakov Kogan
Chief Executive Officer, Principal Financial Officer, Since 2017
Salary: $276,866.00
Bonus: --
Andrei Gudkov
Chief Scientific Officer, Since 2003
Salary: $119,257.00
Bonus: --
Ivan Fedyunin
Director, Since 2018
Salary: --
Bonus: --
Alexander Andryushechkin
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

73 High St
BUFFALO   NY   14203-1149

Phone: +1716.8496810

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

SPONSORED STORIES